Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2021-07-01 00:00:00 ET · period of report 2021-06-30 · accession 0001567619-21-012871 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-01 | 2021-06-30 | APRE | Namouni Fouad | Dir | A - Grant | $0.00 | +4,610 | 4,610 | New | $0 |
| D | 2021-07-01 | 2021-06-30 | APRE | Namouni Fouad | Dir | A - Grant | $0.00 | +22.8K | 22.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-06-30 | A | A | 4,610 | $0.00 | 4,610 | D | — | — | (F1) These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-06-30 | A | A | 22,750 | $0.00 | 22,750 | D | $4.88 · — to 2031-06-30 | 22,750 Common Stock | (F2) The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |